MediLexicon Logo
MediLexicon Logo
Abbreviations        Abbrev Definitions        Dictionary        ICD Codes        Equipment        Hospitals        Drugs        More..
  


Pentoxifylline

Company: Faulding, Mylan Laboratories
Approval Status: Approved July 1997
Treatment for: chronic occlusive arterial disease
Areas: Cardiovascular / Cardiology

| General Information | Clinical Results | Mechanism of Action |


General Information

Pentoxifylline is a 400 mg extended release tablet and the generic equivalent of Trental. It is being marketed by Hoechst Marion Roussel. Pentoxifylline extended release tablets are indicated for the treatment of leg pain caused chronic occlusive arterial disease of the limbs. Patient walking distance and daily activities are limited by the disease. Both Faulding and Mylan are now manufacturing Pentoxifylline.


Clinical Results

In a comparison between aspirin and pentoxifylline in the elderly, the level of pain did not change significantly with either aspirin or pentoxifylline, but patient’s walking distance was extended with the pentoxifylline group.


Mechanism of Action

Pentoxifylline increases red blood cell flexibility and improves blood flow.




< back to top

Pentoxifylline Drug Information

The Pentoxifylline drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.





MediLexicon International Ltd Logo

Privacy Policy   |    Disclaimer   |    Contact / Feedback

MediLexicon International Ltd
Bexhill-on-Sea, UK
MediLexicon International Ltd © 2004-2014 All rights reserved.